Reading INBS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INBS free→Reading INBS? Track it free: the weekly brief, plus an alert if the thesis breaks. No credit card.
Track INBS free→NASDAQHealth CareMedical DevicesSnapshot 2026-06-16
Recent financial performance sits below its industry cohort — worth keeping an eye on, though it has not freshly broken.
Recent financial performance is neutral, and earnings quality cannot be assessed since the company was unprofitable over the past year. Management's recent track record has been fairly steady, but the capital stance is capital unfriendly. Risk is high, and the sector backdrop is a headwind, which could impact performance compared to sector peers, where it is typical. Peer multiples imply a price about 62% above where it trades (it looks cheap on this basis); the read is cheap, value-trap risk, as it trades below peer multiples while recent financials are weak. This analysis is provisional.
Daily closes. Earnings/event dots are placed inline.
A consensus fair price across 2 valuation methods, at three horizons. Current price $2.30. Estimates are diagnostics, not price targets. Short-horizon estimates are close to coin-flips, so confidence is a method-agreement read, not a prediction.
No-growth: today's peer multiple on trailing earnings. The headline read.
Embeds projected growth. Leans optimistic by design. Upside context.
We take the 12-month fair value above and grade our own number — how the market prices this name versus what we'd justify, and where the two diverge.
At $2.30 INBS trades at 1× p/s, below its 3× p/s peer median. Our $11 fair value sits above the price; low confidence. Not investment advice.
One valuation read at a 12-month horizon, plus how price compares to peers and the company's own history.
The price implies about 80% below a flat-multiple fair value, below our forecast of about 24%. This describes what's priced in, not a forecast of the move.
TTM earnings are negative, so the read leans on sales- and cash-flow-based methods rather than P/E. This is a data condition, not a forward call.
No fragility gates fired. Regime (Mania) does not concentrate fragility.
Each factor is a parallel diagnostic with a clear read of what it shows and how names like it have historically fared. Never aggregated into a single score.
Operating income rose in 2 of the last 3 quarter-over-quarter moves. Historically, Health Care names rated neutral grew net income 50% of the time over the next year (vs 57% for the rest of the cohort, n=3115).
Over the trailing year it converted 0.94x of net income into operating cash flow.
Not enough signal yet.
Not enough signal to read sensitivity to the broad stock market, Fed net liquidity, real (inflation-adjusted) rates, long-term interest rates, the US dollar.
12 material management or governance events in the past 24 months, led by capital-allocation actions. Historically, Health Care names rated neutral grew net income 58% of the time over the next year (vs 50% for the rest of the cohort, n=842).
The next print and the backdrop around it (sector regime and the AI cycle). Context for the path, not a forecast of returns.
via XLV
Tailwind = sector leading the S&P 500; headwind = trailing. Both can be constructive. Historically, headwind regimes have averaged stronger forward returns than tailwind.
How management runs the business: capital, margins, balance sheet, and how reliably they guide and deliver.
A guidance track record builds as the company issues and delivers on guidance.
What a normal day, a bad day, and the worst of the last year would mean for a $10,000 position.
On a typical day, $10k can swing ±$302.
How much price usually moves either way.
On a bad day, this stock has moved -$1,104.
A rough but not unusual down day (about the 95th percentile).
In the worst 12 months, $10k could have lost $8,982.
Deepest peak-to-trough drop in the last year.
Past results, not a forecast. Not investment advice.
The most important moves since the prior daily snapshot.
Signal changed from 'mild_favorable' to 'mixed'.
Composite insight fell by 12.0 points (from 10.2 to -1.8).
As of June 16, 2026, the signal label changed to mixed. Risk fell. The sector backdrop remains a headwind, and earnings quality is categorized as loss-making. Management is neutral, while the recent financial performance is also neutral.
as of 2026-06-16
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
No named catalysts to watch right now. Check back after the next earnings report.
Recent news graded against this company's own objectives — whether it reinforces or challenges the thesis, and how confirmed it is.
No graded news catalysts for INBS yet.
Conditional scenarios: if X happens, the view would shift in this direction. These are not predictions.
Recent SEC 8-K filings ranked by likely impact, confidence, and recency.
Results of Operations and Financial Condition. On May 13, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended March 31, 2026. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information furnished in this Current Report on Form 8-K under Item 2.02, including Exhibit 99.1 attached hereto, shall not be deemed “filed” for purposes of Section 18…
Whether the overall read has been drifting up or down lately, and how it's changed since last week.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Long-thesis check; widest uncertainty.
TTM earnings are negative. P/E-based methods drop out and the estimate leans on sales- and cash-flow-based methods. A data condition, not a forward call.
For similar setups historically (n=20,154): about 33% saw a 20%+ drawdown, and roughly 76% of those did not recover within the year. These are historical base rates for the cohort, not a forecast of this stock.
Looks cheaper than most peers in the same business.
Self-history needs ~20 months of data.
Trailing four: 2025-Q3, 2026-Q1, 2026-Q2, 2026-Q3
A side-by-side read on sector standing, valuation, and risk versus peers.
| Stock | Sector standing | Valuation | Risk |
|---|---|---|---|
INBS INTELLIGENT BIO SOLUTIONS INC | Typical Show detailsSector percentile: 41 of 100 | inexpensive | high |
Not investment advice. As of 2026-06-16.
Context label only: describes the market state (e.g. real bear vs narrative panic, healthy uptrend vs late-stage froth). It is not a per-ticker buy/sell signal and does not predict factor performance.
Not investment advice. As of 2026-06-16.
Priorities management has stated in recent disclosures, with status and evidence drawn from earnings calls, filings, and press releases.
Focus on achieving a 36% year-over-year revenue increase for fiscal 2026.
Stated in 2 of last 2 quarters. Revenue grew from $741,134 in 2025-Q2 to $1,060,802 in 2026-Q3, indicating progress towards the 36% year-over-year increase target. The trajectory shows delivering on the growth priority.
“first half fiscal 2026 revenue surpasses $2 million, up 36% year-over-year”
“Total revenue expected to be approximately $2.01 million, representing a 36% increase year-over-year”
Enhance gross profit margins through operational efficiencies and cost management.
Stated in 3 of last 3 quarters. Gross profit increased from $223,113 in 2025-Q2 to $535,381 in 2026-Q3, showing improvement in margins. The trajectory indicates delivering on the margin improvement priority.
“Gross profit increased to $535,381 in 2026-Q3.”
“Gross profit was $459,739.”
Focus on achieving positive cash flow from operations through cost control and revenue growth.
Stated in 2 of last 2 quarters. Cash from operating activities was negative $4,330,574 in 2026-Q3, compared to negative $1,567,515 in 2026-Q2, indicating limited progress towards achieving positive cash flow from operations.
“Cash from operating activities was negative $4,330,574.”
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On March 18, 2026 (the “Grant Date”), upon the prior approval and recommendation of the Compensation Committee (“Committee”) of the Board of Directors (the “Board”) of Intelligent Bio Solutions Inc. (the “Company”), the Board approved by unanimous written consent all matters approved and recommended by the Committee, including grants of time-vestin…
Other Events Awards to Directors On the Grant Date, the Committee also approved time-vesting restricted stock awards to non-employee directors, with an aggregate of 20,000 shares granted under the Plan pursuant to the applicable U.S. Director 2026 Restricted Stock Award Agreement form and AUS/UK Director 2026 Restricted Stock Award Agreement form, vesting on the 12-month anniversary of the Grant Date, subject to each director’s continued service on the Board through the vesting date; all such…
Results of Operations and Financial Condition. On February 12, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing financial results for the fiscal quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, whether made before or after…
Results of Operations and Financial Condition. On February 5, 2026, Intelligent Bio Solutions Inc. (the “Company”), issued a press release (the “Press Release”) announcing preliminary, unaudited revenue results for the fiscal second quarter ended December 31, 2025. A copy of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information contained herein and in the accompanying exhibits shall not be incorporated by reference into any filing of the Company, w…
“Gross profit was $223,113.”
“Cash from operating activities was negative $1,567,515.”